Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
265.9
-3.05 (-1.13%)
Market Cap: 34.30 Bil
Enterprise Value: 33.17 Bil
PE Ratio: 0
PB Ratio: 1,063.60
GF Score: 78/100 Alnylam Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) Transcript
Mar 08, 2022 / 02:50PM GMT
Release Date Price:
$162
(-0.61%)
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
Good morning, everyone. Welcome to day 2 of the 2022 Cowen Healthcare Conference. Thanks for joining us for the Alnylam fireside chat today. I'm covering biotech analyst, Ritu Baral. And with us from Alnylam today, Akshay Vaishnaw, President and Head of R&D for Alnylam.
Akshay, thanks so much for joining us today. Relatively recent promotion for you, end of last year, correct? So congratulations. I do have to say I still love the fuzzy dice in the back. I'm glad you didn't take those down.
Akshay K. Vaishnaw
Alnylam Pharmaceuticals, Inc. - President
I keep those on there for you, Ritu. I'm delighted to be here with you. Thank you.
Questions & Answers
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
Which brings us to my first question of what you think the placebo effect in APOLLO-B is going to be. I'm kidding. You wouldn't rely on
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot